

1 **Genetic overlap between major depression, bipolar disorder and Alzheimer's**
2 **Disease**

3

4 Fernanda C. Dos Santos, PhD^{1*}; Ana Paula Mendes-Silva, PhD¹; Yuliya S. Nikolova,
5 PhD¹; Etienne L. Sibille, PhD^{1,2,3}; Breno Satler Diniz, MD, PhD^{1,2,4*}

6

7 **Institutional affiliations**

8 ^{1.} Campbell Family Mental Health Research Institute, Centre for Addiction and Mental
9 Health (CAMH), Toronto, ON M5T 1R8, Canada

10 ^{2.} Department of Psychiatry, Faculty of Medicine, University of Toronto, ON M5S 1A8,
11 Canada

12 ^{3.} Department of Pharmacology and Toxicology, University of Toronto, ON M5S 1A8,
13 Canada

14 ^{4.} Center on Aging, University of Connecticut Health Center, Farmington, CT 06030,
15 USA

16

17 *** Corresponding authors:**

18 **Fernanda C. Dos Santos**

19 250 College Street

20 Toronto, ON, Canada

21 M5T 1R8

22 Email: fernanda.santos@camh.ca

23 **Breno S. Diniz**

24 250 College Street

25 Toronto, ON, Canada

26 M5T 1R8

27 Email: Breno.Diniz@camh.ca / diniz@uchc.edu

28

29 **Word count:** 3,444

30 **ABSTRACT**

31 *Background:* Mood disorders, including major depression (MD) and bipolar disorder
32 (BD), are risk factors for Alzheimer's disease (AD) and possibly share an overlapping
33 genetic architecture. However, few studies have investigated the shared loci and
34 potential pleiotropy among these disorders.

35 *Methods:* We carried out a systematic analytical pipeline using GWAS data and three
36 complementary (genome-wide, single variant, and gene-level) statistical approaches to
37 investigate the genetic overlap among MD, BD, and AD.

38 *Results:* GWAS summary statistics data from 679,973 individuals were analyzed herein
39 (59,851 MD cases and 113,154 controls; 20,352 BD cases and 31,358 controls; and
40 71,880 AD cases and 383,378 controls). We identified a significant positive genetic
41 correlation between MD and AD ($r_G = 0.162$; s.e. = 0.064; $p = 0.012$), and between BD
42 and AD ($r_G = 0.162$; s.e. = 0.068; $p = 0.018$). We also identified two pleiotropic
43 candidate genes for MD and AD (*TMEM106B* and *THSD7A*) and three for BD and AD
44 (*MTSS2*, *VAC14*, and *FAF1*), and reported candidate biological pathways associated
45 with all three disorders.

46 *Discussion:* Our study identified genetic loci and mechanisms shared by mood disorders
47 and AD. These findings could be relevant to better understand the higher risk for AD
48 among individuals with mood disorders, and to propose new interventions.

49

50 **KEYWORDS:** Alzheimer's disease, Depression, Bipolar disorder, Genetic overlap,
51 Pleiotropy, Genetic correlation, Pathway enrichment analysis

52 1 | INTRODUCTION

53 Mood disorders, including major depression (MD) and bipolar disorder (BD), are risk
54 factors for Alzheimer's disease (AD). History of MD or BD across the lifespan can
55 double the risk of developing AD in older adults¹⁻⁴. The risk is even higher in older adults
56 with concurrent MD and mild cognitive impairment⁵ or those with persistent depressive
57 symptoms⁶. Clinical and epidemiological evidence suggests that mood disorders and
58 AD may share common biological abnormalities that, when triggered in individuals with
59 mood disorders, lead to faster progression to AD⁷. Methodological challenges such as
60 the need for large sample sizes with the longitudinal assessment of mood and cognition,
61 over long follow-up time (ideally 10 years or more), and biospecimens collection limit the
62 direct assessment of possible mechanisms related to the higher risk of AD among
63 individuals with mood disorders^{8,9}. An additional challenge is the high heterogeneity of
64 MD, BD, and AD's pathophysiologic mechanisms.

65 The availability of large datasets (e.g., Psychiatric Genomics Consortium (PGC),
66 International Genomics of Alzheimer's Project (IGAP), UK Biobank) with both clinical
67 characterization and whole-genome analysis, together with advances in mathematical
68 and analytical models, allow the investigation of the genetic overlap among complex
69 disorders without demanding the assessment of both phenotypes in large longitudinal
70 cohorts. Some of these methods, such as cross-trait linkage disequilibrium (LD)
71 regression, bivariate causal mixture model, and pleiotropy-informed conjunctive false
72 discovery rate^{8,10}, employ mathematical and statistical models to summary statistics
73 results of two different phenotypes to evaluate the genetic correlation and polygenic
74 overlap while accounting for possible genetic pleiotropic effects.

75 Previous studies applying these statistical methods to investigate the genetic overlap
76 between AD and mood disorders in the PGC and IGAP cohorts found no genetic
77 correlation (LSDC measure of correlation effects) between AD and MD or between AD
78 and BD⁸. Subsequent studies in non-overlapping samples (Generation Scotland's
79 Scottish Family Health Study (GS:SFHS) and UK Biobank cohorts) also failed to detect
80 genetic overlap between AD and MD, either through genetic correlation or a
81 complementary polygenic risk score (PRS) approach¹¹. Nonetheless, Drange et al.
82 (2019)¹² recently found evidence of two pleiotropic loci for AD and BD using a
83 pleiotropy-informed conjunctive false discovery rate method (conjFDR)¹³, despite not
84 finding a significant genetic correlation between both conditions. Drange's study
85 highlights the importance of using complementary strategies to assess genetic overlap
86 among psychiatric disorders, given their genetic complexity and heterogeneity and the
87 limitations of the currently available analytical methods⁹.

88 In the present study, we carried out a multi-level analytical approach to investigate the
89 genetic overlap between mood disorders (MD and BD) and AD. We first applied a
90 genome-wide statistical approach, followed by a single-variant and a gene-based
91 network approach. Given that these phenotypes are primarily driven by regulatory
92 networks composed of multiple genes, often with small effects¹⁴, we also evaluated the
93 overlap of genes with minimal effects over each disorder and their shared biological
94 pathways¹⁵. Since the individuals with mood disorders were on average younger than
95 those with AD, we assumed that mood disorders would precede AD's development in all
96 analyses.

97 **2 | METHODS**

98 **2.1 | Analyzed datasets**

99 Summary statistics from three genome-wide association studies and meta-analyses
100 were used to obtain candidate risk loci for mood disorders and AD. Summary statistics
101 from MD and BD studies were extracted from the PGC2-MDD and PGC2-BD,
102 respectively^{16,17}. A summary statistics of an AD GWAS meta-analysis including the
103 cohorts PGC-ALZ, IGAP and ADSP¹⁸ were assessed to account for AD candidate
104 variants. There is few or no overlap of samples between mood disorders and AD
105 databases. Supplementary material provides additional information about each dataset.

106 **2.2 | Genetic correlation**

107 Linkage Disequilibrium Score Regression (LDSR) bivariate genetic correlations based
108 on genome-wide SNPs (r_G) were estimated for the pairs, AD vs. BD, and AD vs. MD
109 using the LDSC software v1.0.0⁸. This method uses the relationship between GWAS
110 test statistics (X^2) and the linkage disequilibrium score of a given SNP to access the
111 portion of heritability attributed to the same SNP in different studies and the genetic
112 covariance of this given SNP across traits. The genetic correlation is calculated by
113 normalizing the genetic covariance by the heritability estimates obtained from each trait
114 (see supplementary material for additional information).

115 **2.3 | Polygenic overlap and pleiotropy**

116 Polygenic overlap accounts for the fraction of genetic variants with a non-zero genetic
117 effect that is causally associated with both traits over the overall number of variants

118 identified as causal for each trait. Polygenic overlap was estimated using two methods.
119 First, the polygenic overlap was estimated using a bivariate causal mixture model
120 implemented in MiXer v1.2.0 software¹⁹. This method uses a bivariate causal mixture
121 model, an expansion of the cross-trait LDSR method, in which a relaxed infinitesimal
122 assumption is applied (see supplementary material for additional information).
123 We additionally used a pleiotropy-informed conditional false discovery rate (condFDR
124 and conjFDR) to assess common variants associated with AD and mood disorders
125 (pleioFDR v1.0.0 software)¹³. This method detects shared susceptibility loci in related
126 phenotypes by applying a Bayesian method that tests the association of genetic
127 variants to the principal phenotype when conditional on a second and related phenotype
128 using the posterior probability of a false positive association^{12,13}.

129 **2.4 | Gene-based GWAS and gene-based overlap**

130 We performed a gene-based association approach to identify potential gene overlaps
131 between mood disorder and AD using Multi-marker Analysis of GenoMic Annotation
132 (MAGMA) v1.06 software²⁰. Genes were annotated by considering SNPs' position in a
133 range interval containing 50 kb upstream and downstream the gene. We generated two
134 gene lists for each disorder: A) a list of genes associated with the disorder under a 5%
135 Bonferroni correction for multiple testing; and B) a broader list of all genes showing non-
136 zero effect (i.e., nominal p-value < 0.05) (including those in List A) to guarantee that
137 even genes with small effects would be evaluated. Lists A and B were compared
138 between pairs of disorders, and a list of overlapping genes under each threshold was
139 obtained. The gene model 'multi' was applied to obtain the association tests by the

140 genes. Comparisons of overlapping among gene sets were performed considering two
141 thresholds: 1) a Bonferroni corrected p-value ($\alpha=0.05$), and 2) a non-zero effect
142 ($Z>|\pm 1.96|$ or $p<0.05$). The lists of overlapping genes considering a non-zero effect for
143 both disorders were used further as inputs for functional analyses.

144 **2.5 | Gene set enrichment analysis**

145 Gene set enrichment analyses were performed on lists of overlapping genes among
146 pairs of phenotypes (genes with non-zero effect) using FUMA v1.3.6^{21,22}. In this
147 analysis, all genes in Ensembl v92 were selected as background and a minimum of
148 overlapping genes with gene sets ≥ 2 was used. Fifty-four tissue types from GTEx v8
149 were used to search for expression enrichment by tissue. Q-values were calculated
150 using the Benjamini-Hochberg procedure for accounting for multiple testing.

151 **2.6 | Pathway Enrichment Analysis**

152 To understand the biological processes affected by the overlapping genes between
153 mood disorders and AD, we performed an enrichment map analysis to discover
154 biological processes and pathways associated with the identified gene. For each given
155 gene list, pathway and process enrichment analysis were carried out using g:Profiler
156 (<https://biit.cs.ut.ee/gprofiler>) including the following ontology sources: GO Biological
157 Processes, Reactome, and KEGG (Kyoto encyclopedia of genes and genomes). All
158 genes in the genome were used as the enrichment background. Each network was
159 visualized using Cytoscape 3.8.2 and the Enrichment Map (version 3.3)²³. The Auto
160 Annotate and Cluster Maker 2 apps were used for the analysis. The terms with a p-
161 value < 0.05 , q-value < 0.05 , a minimum count of 3, Jaccard and overlap combined >

162 0.375 and edge cutoff ≥ 0.5 were collected and grouped into clusters based on their
163 membership similarities. The p-values were calculated based on the accumulative
164 hypergeometric distribution²⁴ and q-values were calculated using the Benjamini-
165 Hochberg method for multiple testing²⁵. To further capture the relationship between the
166 terms, the enriched terms were plotted in a network, where edges connected terms with
167 a similarity > 0.5 . Each node represents an enriched term and is colored first by its
168 cluster ID generated using the Markov cluster algorithm (MCL)²⁶ (see supplementary
169 material for additional information).

170 **3 | RESULTS**

171 **3.1 | Positive genetic correlation between mood disorders and AD**

172 We initially selected three large recently published GWAS studies for MD¹⁶ (59,851
173 cases and 113,154 controls), BD¹⁷ (20,352 cases and 31,358 controls), and AD¹⁸
174 (71,880 cases and 383,378 controls) to obtain summary statistics and evaluate the
175 genetic correlation between these conditions (Supplementary information). We found a
176 small but significant genetic correlation between MD and AD ($r_G = 0.162$; s.e. = 0.064; p
177 = 0.012), and between BD and AD ($r_G = 0.162$; s.e. = 0.068; $p = 0.018$). These results
178 indicate that mood disorders and AD share causal variants, with small to moderate
179 effect sizes.

180 **3.2 | Genetic overlap and pleiotropy between mood disorders and AD**

181 We next investigated the extent of the genetic overlap between mood disorders and AD
182 to capture the mixture of effect directions across shared variants. We estimated the

183 number of shared variants and the correlation of effects (ρ) only among them, using a
184 bivariate causal mixture model (MiXer)¹⁹. MiXer models are optimized for variants with
185 small effect sizes that do not reach GWAS significance¹⁹. AD shows a genetic
186 architecture characterized by lower polygenicity than other complex disorders, with
187 some variants, such as the APOE locus, showing very large effects^{9,27}. Therefore, to
188 better accommodate AD variants in the MiXer model, we removed variants mapping to
189 APOE locus (chr19: 45,000,000- 45,800,000 bp) for this analysis and fitted a model
190 based only on SNPs that did not reach GWAS significance (see supplementary material
191 for additional information)¹⁹. Our results indicated an estimate of 371 causal variants
192 shared between MD and AD from a total of 27,636 causal variants (Table 1). Despite
193 the low polygenic overlap, we found a very strong correlation of effects within shared
194 causal variants ($\rho_{12} = 0.99$) (Table 1).

195 Given the MiXer model's limitations, we further evaluated the genetic overlap by a
196 pleiotropy-informed conditional false discovery rate (condFDR and conjFDR¹³). This
197 method improves the detection of shared susceptibility loci in related phenotypes by
198 applying a Bayesian method that tests the association of genetic variants to the
199 principal phenotype when conditional on a second and related phenotype using the
200 posterior probability false-positive association¹³. We identified one independent
201 pleiotropic locus for AD and MD at a significance level of conjFDR<0.05 (Figure 1a and
202 Table 1). This locus maps to chromosome 7 and contains 7 SNPs mapping nearby two
203 genes, *TMEM106B* and *THSD7A*, which were mapped using SNPinfo Web Server²⁸.

204 For the BD and AD analyses, MiXer estimated 360 causal variants shared between BD
205 and AD, from a total of 10,256 causal variants when considering both disorders (Table

206 1). A moderate positive correlation was found among shared variants ($\rho_{12}=0.545$).
207 This result indicates that despite the low polygenic overlap between BD and AD, there is
208 a significant but mixed correlation between the shared causal variants. The conjFDR
209 also identified one pleiotropic locus (conjFDR<0.05) mapping to the chromosome 1 and
210 containing 3 associated SNPs, all mapping nearby the *FAF1* gene (Figure 1b and Table
211 1). Overall, these findings suggest a mixed pattern of effects among overlapping
212 variants exists between BD and AD, in contrast with the MD and AD results. A full list of
213 the loci found in this analysis can be found on Supplementary Table 1.

214 **3.3 | Gene overlaps between mood disorders and AD and related biological** 215 **pathways**

216 MAGMA analysis showed 220 and 35 genes associated with AD and MD, respectively
217 (Supplementary tables 2 and 3). There were no overlapping genes between MD and AD
218 after Bonferroni correction. However, considering all genes with non-zero effects over
219 both disorders, we identified 158 genes overlapping genes (Supplementary table 4).
220 We included the 158 overlapping genes with non-zero effect found in MAGMA analysis
221 to interrogate the affected biological pathways in the enrichment analysis. The
222 Enrichment Map analysis²³ returned 291 gene clusters for terms related to the cellular
223 response to amyloid-beta, cell growth and differentiation, respiratory electron transport
224 chain, synapse organization, immune-inflammatory response, membrane trafficking,
225 gene and protein regulation, among others (Figure 2; the full result is available in
226 Supplementary table 5). A highly interconnected pattern can be observed in this
227 network, suggesting different sets of genes (with different effect sizes over MD and AD)

228 impact biological pathways involved in both disorders, indicating potential mechanistic
229 links between these disorders (Figure 2).

230 MAGMA analysis identified 245 and 220 genes associated with BD and AD,
231 respectively (Bonferroni corrected p-value < 0.05) (Supplementary tables 2 and 6). We
232 found 2 overlapping genes mapped to the same locus of chromosome 16: *MTSS2* and
233 *VAC14*. Enrichment Map analysis detected 326 gene clusters related to cell cycle, cell
234 growth and differentiation, cell-cell signaling, synapse organization, neuron death,
235 respiratory electron transport chain, immune inflammatory response, membrane
236 trafficking, gene and protein regulation, lipid metabolism and absorption, among others
237 (p-value<0.05 and q-value<0.05) (Figure 3; the full result is available in Supplementary
238 table 7). The six most enriched clusters involved inflammatory response, programmed
239 cell death, protein and gene regulation, membrane trafficking, and tissue development
240 (Supplementary table 7). The biological pathways analysis from overlapping genes
241 between BD and AD showed a strong relationship between these clusters and neuronal
242 development, neuron death, and synapse organization clusters. Other gene clusters
243 showed a cellular senescence mechanism involved in cell cycle regulation and a
244 programmed cell death stress-activated. As with MD and AD, a highly interconnected
245 network can be observed when analyzing the overlapping gene sets between BD and
246 AD (Figure 3).

247 **3.4 | Analysis of tissue expression of overlapping genes in mood disorders and** 248 **AD showed enrichment for brain tissues**

249 We investigated the tissue expression of overlapping genes between mood disorders
250 and AD using the GTEX (v8) data in the FUMA GENE2FUNC application, covering 54
251 human tissues^{21,22}. From the 158 genes overlapping between MD and AD, 156 were
252 found in the GTEX database. These genes were mainly expressed in all nervous
253 tissues except for the cerebellum, pituitary, and tibial nerve (corrected p-value < 0.05)
254 (Figure 4a). Likewise, from the 279 overlapping genes between BD and AD, 278 were
255 identified in the GTEX database. As with MD and AD analysis, these genes were mainly
256 expressed in nervous tissues (Figure 4b). These results corroborate that genes related
257 to mood disorders and AD are mostly involved in nervous system functions.

258 **4 | DISCUSSION**

259 In this study, we applied a systematic analytical framework based on statistical methods
260 and functional analyses to investigate the common genetic architecture between mood
261 disorders and AD. Our main findings were a significant, positive genetic correlation
262 between mood disorders and AD and the evidence of overlapping and pleiotropic loci
263 among these disorders. To the best of our knowledge, our study is the first to provide a
264 comprehensive analysis of potential overlapping genetic and biological pathways
265 between mood disorders and AD and to identify pleiotropic loci contributing to MD and
266 AD. Importantly, our analyses showed that the overlapping genes were mainly
267 expressed in brain tissues.

268 In contrast with the previous studies^{8,11,12}, we showed a significant genetic correlation
269 among MD, BD, and AD. A possible explanation for our results was the use of larger
270 publicly available databases compared to previous studies, increasing the power to
271 detect statistically significant correlations of effects by cross-trait LDSR method. Using a
272 single-variant approach, we found two candidate genes in a pleiotropy locus in MD and
273 AD, expressed in the CNS and previously associated with essential functions described
274 for both disorders. The Transmembrane Protein 106B (*TMEM106B*) is a protein-coding
275 gene expressed in many tissues, including the brain. It is involved in dendrite
276 morphogenesis, maintenance, and branching by regulating lysosomal trafficking and
277 organization. Mutations in *TMEM106B* resulting in elevated expression of this protein
278 have been identified as a risk factor for MD and AD in independent GWAS studies^{16,29}.
279 The second candidate identified was the Thrombospondin Type 1 Domain Containing
280 7A (*THSD7A*), a protein-coding gene involved in endothelial cell migration and
281 cytoskeletal organization. It is highly expressed in the CNS, and variants of the *THSD7A*
282 gene are associated with educational attainment³⁰, depressive symptoms³¹, and AD³² in
283 recent GWAS. We identified one pleiotropic gene for BD and AD using the same
284 approach, the Fas Associated Factor 1 (*FAF1*). This gene codifies an ubiquitin-binding
285 protein expressed in various tissues, including the nervous system. FAF1 initiates or
286 enhances apoptosis through the interaction with the FAS antigen (TNFRSF6) and
287 activation of caspase-8 and caspase-3^{33,34} and regulates necrosis after oxidative stress
288 in neuronal degeneration³⁵. *FAF1* has been associated with depressive symptoms and
289 alcohol consumption in a GWAS³⁶. These are important findings since they can lead to

290 the development of interventions to mitigate the risk of AD among individuals with mood
291 disorders.

292 Enrichment map analysis showed common biological pathways shared by MD and
293 AD²³. First, we identified biological processes involved in the cellular response to
294 amyloid-beta. The abnormal processing and metabolism of the amyloid-beta protein and
295 the secondary cellular responses to the amyloid-beta insult are viewed as early and
296 primary pathophysiologic mechanisms of AD^{37,38}. Other biological processes shared
297 between MD and AD include regulating inflammatory response, neurotrophic support,
298 neuronal death, and mitochondrial function. Abnormalities in these processes are
299 described in AD and are well-established consequences of amyloid-beta pathology.
300 Based on our results, we hypothesize the presence of a structured biological network
301 linking MD and AD. In this scenario, individuals with MD are more susceptible to the
302 abnormal metabolism and the downstream cellular responses to the amyloid-beta,
303 leading to the activation of neurotoxic biological cascades, with negative consequences
304 to brain health and higher risk of AD. Our results also partially explain why individuals
305 with recurrent depressive episodes, those with severe and persistently high trajectories
306 of depressive symptoms, and those with concurrent cognitive impairment display a
307 highest risk of AD³⁹⁻⁴¹.

308 There is less robust data on the association between BD and AD, but a recent meta-
309 analysis shows that BD is a significant risk factor for AD, having a greater odds ratio
310 than MD and AD². Although the genetic correlation between BD and AD was similar to
311 the one between MD and AD, our additional analyses showed a more significant genetic
312 overlap between BD and AD than MD and AD, which can partially explain the higher

313 risk of AD among individuals with BD. Enrichment Map analyses revealed three major
314 pathway modules related to the genetic overlap between BD and AD. The first cluster is
315 mostly related to the nervous system homeostasis maintenance and metabolic activity.
316 Amid these pathways, amyloid-beta clearance, the calcium signaling pathway,
317 serotonergic synapse, and neurotrophin signaling have been previously associated with
318 AD physiopathology⁴²⁻⁴⁴. In a second cluster, the pathways were primarily related to
319 immune response, cell growth and survival, and neuroendocrine pathways.
320 Interestingly, these pathway modules were highly interconnected and acted as an
321 immune-endocrine-neuronal regulatory network. Also, several pathways related to
322 intestinal absorption were extensively connected with inflammatory response and
323 neuronal development clusters. These results suggest the involvement of a gut–
324 immune-brain axis as a shared mechanism between BD and AD⁴⁵⁻⁵⁰. The third cluster of
325 pathways involved cell communication, cell cycle regulation, apoptosis, and lipid
326 metabolism, previously associated with both BD and AD pathogenesis^{33,34,36,51-54}.

327 The current results should be viewed considering the study limitations. Although the use
328 of summary statistics of GWAS is a convenient and useful method to investigate
329 polygenic overlap, it does not provide the data for each individual in the original studies.
330 Therefore, decisions taken on the original studies regarding study design and statistical
331 methods could impact the current results. Second, the original studies' sample
332 characteristics may have influenced our results, e.g., the high heterogeneity of the
333 original studies samples (composed of many cohorts), sex and age distribution,
334 ascertainment of major depression, bipolar disorder, and AD caseness. The MiXer
335 analysis results should be viewed with caution, given the genetic architecture of AD and

336 its impact on the model fitting used to evaluate individual variants' effects in AD. Finally,
337 the choice to work with a list of genes with non-zero effect for the functional analyses (p-
338 value uncorrected for multiple testing) could lead to the selection of genes with spurious
339 associations to each disorder. However, to deal with this possible limitation, posterior
340 steps including multiple testing corrections would mitigate the impact of this
341 methodological choice and increase the confidence about the pathways and biological
342 mechanisms found in the present study. A similar approach has been successfully
343 adopted by Cui et al. (2018)¹⁵.

344 In summary, the multi-level approach to identifying the genetic overlap between mood
345 disorders and AD revealed a complex network of genetic overlap affecting multiple
346 biological pathways essential for the neuronal function and CNS homeostasis and
347 hormesis (the adaptive responses of biological systems to challenges throughout the
348 system). Our study identified possible mechanisms linking mood disorders and AD that
349 can be relevant to the development of novel therapeutic interventions to mitigate the risk
350 of AD among vulnerable individuals.

351 **ACKNOWLEDGMENTS**

352 We thank the authors of Jansen et al., 2019¹⁸, Psychiatric Genetic Consortium Bipolar
353 Disorder Working Group (PGC-BIP)¹⁷ and Psychiatric Genetic Consortium Major
354 Depressive Disorder Working Group (PGC-MDD)^{16,29} for making summary statistics
355 available. This work was supported by 'CAMH's internal funding mechanisms. Dr. Diniz
356 is supported by NIH grants R01MH115953 and R01MH118311.

357 **CONFLICTS OF INTEREST**

358 The authors declare that they have no conflict of interest.

359 **AUTHOR CONTRIBUTIONS**

360 F.C.D.S. contributed to study design and conducted all the genetic, computational and
361 statistical analyses for genetic overlap, interpretation of results and wrote the
362 manuscript draft. A.P.M.S. performed the enrichment analyses, interpretation and
363 substantially contributed to the manuscript draft by describing enrichment analyses
364 methods and findings. Y.S.N. and E.S. contributed to manuscript editing and critical
365 intellectual input about the analysis and results. B.S.D developed the study concept,
366 oversaw all analyses and all stages of manuscript preparation. All authors reviewed and
367 approved the manuscript before submission.

368 **REFERENCES**

- 369 1. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF, 3rd. Late-life depression and
370 risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis
371 of community-based cohort studies. *Br J Psychiatry*. 2013;202(5):329-335.
- 372 2. Diniz BS, Teixeira AL, Cao F, et al. History of Bipolar Disorder and the Risk of Dementia:
373 A Systematic Review and Meta-Analysis. *Am J Geriatr Psychiatry*. 2017;25(4):357-362.
- 374 3. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and Risk for
375 Alzheimer Disease: Systematic Review, Meta-analysis, and Metaregression Analysis.
376 *Archives of General Psychiatry*. 2006;63(5):530-538.
- 377 4. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms
378 and risk of dementia. *The Framingham Heart Study*. 2010;75(1):35-41.
- 379 5. Tan EY, Köhler S, Hamel RE, Muñoz-Sánchez JL, Verhey FR, Ramakers IH. Depressive
380 symptoms in mild cognitive impairment and the risk of dementia: a systematic review
381 and comparative meta-analysis of clinical and community-based studies. *Journal of*
382 *Alzheimer's Disease*. 2019;67(4):1319-1329.
- 383 6. Singh-Manoux A, Dugravot A, Fournier A, et al. Trajectories of Depressive Symptoms
384 Before Diagnosis of Dementia: A 28-Year Follow-up Study. *JAMA Psychiatry*.
385 2017;74(7):712-718.
- 386 7. Gatchel JR, Rabin JS, Buckley RF, et al. Longitudinal association of depression
387 symptoms with cognition and cortical amyloid among community-dwelling older adults.
388 *JAMA network open*. 2019;2(8):e198964-e198964.
- 389 8. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across
390 human diseases and traits. *Nat Genet*. 2015;47(11):1236-1241.
- 391 9. Bellou E, Stevenson-Hoare J, Escott-Price V. Polygenic risk and pleiotropy in
392 neurodegenerative diseases. *Neurobiol Dis*. 2020;142:104953.

- 393 10. Smeland OB, Frei O, Fan CC, Shadrin A, Dale AM, Andreassen OA. The emerging
394 pattern of shared polygenic architecture of psychiatric disorders, conceptual and
395 methodological challenges. *Psychiatr Genet.* 2019;29(5):152-159.
- 396 11. Gibson J, Russ TC, Adams MJ, et al. Assessing the presence of shared genetic
397 architecture between Alzheimer's disease and major depressive disorder using genome-
398 wide association data. *Transl Psychiatry.* 2017;7(4):e1094.
- 399 12. Drange OK, Smeland OB, Shadrin AA, et al. Genetic Overlap Between Alzheimer's
400 Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes. *Front Neurosci.*
401 2019;13:220.
- 402 13. Andreassen OA, Thompson WK, Schork AJ, et al. Improved detection of common
403 variants associated with schizophrenia and bipolar disorder using pleiotropy-informed
404 conditional false discovery rate. *PLoS Genet.* 2013;9(4):e1003455.
- 405 14. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to
406 Omnigenic. *Cell.* 2017;169(7):1177-1186.
- 407 15. Cui P, Ma X, Li H, Lang W, Hao J. Shared Biological Pathways Between Alzheimer's
408 Disease and Ischemic Stroke. *Front Neurosci.* 2018;12:605.
- 409 16. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44
410 risk variants and refine the genetic architecture of major depression. *Nat Genet.*
411 2018;50(5):668-681.
- 412 17. Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci
413 associated with bipolar disorder. *Nature genetics.* 2019;51(5):793-803.
- 414 18. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new
415 loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet.*
416 2019;51(3):404-413.

- 417 19. Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies
418 polygenic overlap between complex traits beyond genetic correlation. *Nat Commun.*
419 2019;10(1):2417.
- 420 20. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
421 analysis of GWAS data. *PLoS Comput Biol.* 2015;11(4):e1004219.
- 422 21. Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and
423 annotation of genetic associations with FUMA. *Nature communications.* 2017;8(1):1-11.
- 424 22. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. FUMA: Functional mapping
425 and annotation of genetic associations. *European Neuropsychopharmacology.*
426 2019;29:S789-S790.
- 427 23. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based
428 method for gene-set enrichment visualization and interpretation. *PloS one.*
429 2010;5(11):e13984.
- 430 24. Zar JH. *Biostatistical analysis.* Pearson Education India; 1999.
- 431 25. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing.
432 *Statistics in medicine.* 1990;9(7):811-818.
- 433 26. Vlasblom J, Wodak SJ. Markov clustering versus affinity propagation for the partitioning
434 of protein interaction graphs. *BMC bioinformatics.* 2009;10(1):1-14.
- 435 27. Neuner SM, Julia T, Goate AM. Genetic architecture of Alzheimer's disease.
436 *Neurobiology of disease.* 2020:104976.
- 437 28. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into
438 functional SNP selection for genetic association studies. *Nucleic acids research.*
439 2009;37(suppl_2):W600-W605.
- 440 29. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression
441 identifies 102 independent variants and highlights the importance of the prefrontal brain
442 regions. *Nat Neurosci.* 2019;22(3):343-352.

- 443 30. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a
444 genome-wide association study of educational attainment in 1.1 million individuals.
445 *Nature genetics*. 2018;50(8):1112-1121.
- 446 31. Baselmans BM, Jansen R, Ip HF, et al. Multivariate genome-wide analyses of the well-
447 being spectrum. *Nature genetics*. 2019;51(3):445-451.
- 448 32. Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. A novel Alzheimer disease locus
449 located near the gene encoding tau protein. *Molecular psychiatry*. 2016;21(1):108-117.
- 450 33. Ryu S-W, Lee S-J, Park M-Y, Jun J-i, Jung Y-K, Kim E. Fas-associated factor 1, FAF1,
451 is a member of Fas death-inducing signaling complex. *Journal of Biological Chemistry*.
452 2003;278(26):24003-24010.
- 453 34. Park MY, Ryu SW, Kim KD, Lim JS, Lee ZW, Kim E. Fas-associated factor-1 mediates
454 chemotherapeutic-induced apoptosis via death effector filament formation. *International*
455 *journal of cancer*. 2005;115(3):412-418.
- 456 35. Yu C, Kim B-s, Kim E. FAF1 mediates regulated necrosis through PARP1 activation
457 upon oxidative stress leading to dopaminergic neurodegeneration. *Cell Death &*
458 *Differentiation*. 2016;23(11):1873-1885.
- 459 36. Edwards AC, Aliev F, Bierut LJ, et al. Genome-wide association study of comorbid
460 depressive syndrome and alcohol dependence. *Psychiatric genetics*. 2012;22(1):31.
- 461 37. Jack Jr CR, Holtzman DM. Biomarker modeling of Alzheimer's disease. *Neuron*.
462 2013;80(6):1347-1358.
- 463 38. De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*.
464 2016;164(4):603-615.
- 465 39. Mourao RJ, Mansur G, Malloy-Diniz LF, Castro Costa E, Diniz BS. Depressive
466 symptoms increase the risk of progression to dementia in subjects with mild cognitive
467 impairment: systematic review and meta-analysis. *Int J Geriatr Psychiatry*.
468 2016;31(8):905-911.

- 469 40. Gallagher D, Kiss A, Lanctot K, Herrmann N. Depression and Risk of Alzheimer
470 Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among
471 Older Adults with Depression. *Am J Geriatr Psychiatry*. 2018;26(8):819-827.
- 472 41. Kaup AR, Byers AL, Falvey C, et al. Trajectories of Depressive Symptoms in Older
473 Adults and Risk of Dementia. *JAMA Psychiatry*. 2016;73(5):525-531.
- 474 42. Egorova P, Popugaeva E, Bezprozvanny I. Disturbed calcium signaling in
475 spinocerebellar ataxias and Alzheimer's disease. *Semin Cell Dev Biol*. 2015;40:127-133.
- 476 43. Gryglewski RJ, Szczeklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin
477 and iloprost on generation of superoxide anions by human polymorphonuclear
478 leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. *Biochem*
479 *Pharmacol*. 1987;36(24):4209-4213.
- 480 44. Perez SE, He B, Nadeem M, et al. Resilience of precuneus neurotrophic signaling
481 pathways despite amyloid pathology in prodromal Alzheimer's disease. *Biol Psychiatry*.
482 2015;77(8):693-703.
- 483 45. Kim YK, Shin C. The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders:
484 Pathophysiological Mechanisms and Novel Treatments. *Curr Neuropharmacol*.
485 2018;16(5):559-573.
- 486 46. Scheperjans F. Can microbiota research change our understanding of
487 neurodegenerative diseases? *Neurodegener Dis Manag*. 2016;6(2):81-85.
- 488 47. Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the
489 microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic
490 and neurodegenerative diseases. *Pharmacol Ther*. 2016;158:52-62.
- 491 48. Catanzaro R, Anzalone M, Calabrese F, et al. The gut microbiota and its correlations
492 with the central nervous system disorders. *Panminerva Med*. 2015;57(3):127-143.

- 493 49. Genedi M, Janmaat IE, Haarman B, Sommer IEC. Dysregulation of the gut-brain axis in
494 schizophrenia and bipolar disorder: probiotic supplementation as a supportive treatment
495 in psychiatric disorders. *Curr Opin Psychiatry*. 2019;32(3):185-195.
- 496 50. Flowers SA, Ward KM, Clark CT. The gut microbiome in bipolar disorder and
497 pharmacotherapy management. *Neuropsychobiology*. 2020;79(1-2):43-49.
- 498 51. Alghamdi TA, Ho CY, Mrakovic A, Taylor D, Mao D, Botelho RJ. Vac14 protein
499 multimerization is a prerequisite step for Fab1 protein complex assembly and function.
500 *Journal of Biological Chemistry*. 2013;288(13):9363-9372.
- 501 52. Schulze U, Vollenbroeker B, Braun DA, et al. The Vac14-interaction network is linked to
502 regulators of the endolysosomal and autophagic pathway. *Molecular & Cellular*
503 *Proteomics*. 2014;13(6):1397-1411.
- 504 53. Zhang Y, Zolov SN, Chow CY, et al. Loss of Vac14, a regulator of the signaling lipid
505 phosphatidylinositol 3, 5-bisphosphate, results in neurodegeneration in mice.
506 *Proceedings of the National Academy of Sciences*. 2007;104(44):17518-17523.
- 507 54. Lenk GM, Szymanska K, Debska-Vielhaber G, et al. Biallelic mutations of VAC14 in
508 pediatric-onset neurological disease. *The American Journal of Human Genetics*.
509 2016;99(1):188-194.

510

511 **FIGURE LEGENDS**

512 **Figure 1. Conjunction conditional FDR Q value for SNP association with AD**
513 **conditioned to a) MD and to b) BD. A genome-wide significant line (dashed) was**
514 **drawn at $-\log_{10}(0.05 \text{ FDR})$. Pleiotropic loci are circled in black.**

515

516 **Figure 2. Common biological pathways between Major Depressive Disorder and**
517 **Alzheimer's Disease.** A very interconnected pattern can be observed in this network,
518 suggesting that sets of genes including genes shared between these disorders (with
519 different effect sizes over MD and AD) impact a same biological pathway or even
520 different biological pathways involved in these disorders. These genes could then
521 indirectly influence the clinical overlap of them.

522

523 **Figure 3. Common biological pathways between Bipolar Disorder and Alzheimer's**
524 **Disease.** A very interconnected pattern can be observed in this network, suggesting
525 that sets of genes including genes shared but with different effect sizes over BD and AD
526 impact a same biological pathway or even different biological pathways involved in
527 these disorders. These genes could then indirectly influence the clinical overlap of them.

528

529 **Figure 4. Pre-calculated differentially expressed genes (DEG) sets created using**
530 **FUMA for a) MD and AD overlapping genes list and b) for BD and AD overlapping**
531 **genes.** Enrichment analyses were performed using GTEX v.8 54 tissue types database.
532 DEG sets are obtained by a two-sided t-test per tissue versus all the remaining tissues.

533 Significantly enriched DEG sets (P Bonferroni < 0.05) are highlighted in red. The -
534 $\log_{10}(P$ values) refers to the probability of the hypergeometric test. Neural tissues are
535 highlighted in bold.

536 **TABLES**

537 **Table 1. a) Results of MiXer cross-trait analysis for 'Alzheimer's disease (AD),**
 538 **Major depression disorder (MD) and Bipolar disorder for each thousand variants.**
 539 **b) Conjunction FDR; pleiotropic loci in AD and MD (AD&MD) and in AD and BD**
 540 **(AD&BD).**

MiXER: Bivariate causal mixed model

Trait 1	Trait 2	n12	n1	n2	rho12
AD	MD	0.371	7.41E-09	27.265	0.999
AD	BD	0.360	0.0111	9.885	0.545

Conjunctional FDR

Traits	Locus	SNP	Chr	Position	Neighbour gene	distance (bp)	conjFDR
AD&MD	1	rs5011432	7	12235193	<i>TMEM106B</i>	17742 8218	0.042
		rs10234805	7	12220068	<i>TMEM106B</i>	2617 23343	0.049
		rs6948844	7	12232373	<i>TMEM106B</i>	14922 11038	0.049
		rs10278257	7	12220088	<i>TMEM106B</i>	2637 23323	0.049
		rs3807865	7	12216927	<i>THSD7A TMEM106B</i>	-378578 -524	0.050
		rs12699323	7	12219887	<i>TMEM106B</i>	2436 23524	0.050
		rs7808568	7	12237777	<i>TMEM106B</i>	20326 5634	0.050
AD&BD	1	rs7543272	1	50841690	<i>FAF1</i>	162167 356834	0.036
		rs3789586	1	50826910	<i>FAF1</i>	147387 371614	0.043
		rs11205728	1	50765471	<i>FAF1</i>	85948 433053	0.048

541 Columns: n12 – estimated number of shared causal variants, reported in thousands; n1 (n2)– estimated number of causal variants,
 542 unique to trait 1 (trait 2), reported in thousands; rho12 – correlation of effect sizes in shared polygenic component; Chr:
 543 chromosome;

544 **SUPPLEMENTARY FIGURE LEGENDS**

545 **Supplementary Figure 1. Methodological flowchart.**

546 **SUPPLEMENTARY TABLE TITLES**

547 **Supplementary table 1. Conditional and Conjunctive FDR for Alzheimer's**
548 **disease (AD) loci given Major depression (MD) (AD|MD); and for Alzheimer's**
549 **disease (AD) loci given Bipolar disorder (BD) (AD|BD).**

550

551 **Supplementary table 2. Gene-based GWAS results for Alzheimer's disease.**

552

553 **Supplementary table 3. Gene-based GWAS results for Major Depression.**

554

555 **Supplementary table 4. Overlapping genes for AD&MD (Spreadsheet 1) and**
556 **AD&BD (Spreadsheet 2).**

557

558 **Supplementary table 5. Node details for EnrichmentMap analysis of overlapping**
559 **genes between Alzheimer's disease and Major Depression.**

560



561 **Supplementary table 6. Gene-based GWAS results for Bipolar Disorder.**

562


563 **Supplementary table 7. Node details for EnrichmentMap analysis of overlapping**
564 **genes between Alzheimer's disease and Bipolar Disorder.**

a


medRxiv preprint doi: <https://doi.org/10.1101/2021.05.01.21256220>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**b**

Common Biological Pathways Between Major Depressive Disorder and Alzheimer's Disease




Common Biological Pathways Between Bipolar Disorder and Alzheimer's Disease



bioRxiv preprint doi: <https://doi.org/10.1101/2023.07.14.551101>; this version posted July 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

-log₁₀ P-value


a



DEG (both side)

-log₁₀ P-value

b



DEG (both side)

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.04.21261101>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.